| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/04/2001 | WO2001000663A2 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | WO2001000648A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | WO2001000245A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000244A2 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 01/04/2001 | WO2001000238A1 TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000236A1 Prevention of type 1 diabetes and other non-polio enterovirus diseases |
| 01/04/2001 | WO2001000234A2 Methods and compositions for engineering of attenuated vaccines |
| 01/04/2001 | WO2001000231A2 Use of cpg as an adjuvant for malaria vaccine |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000225A1 Hla binding peptides and their uses |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2000064400A3 Methods for treating congestive heart failure |
| 01/04/2001 | WO2000061611A3 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 01/04/2001 | WO2000061069A3 Methods and compositions for use in the treatment of hyperlipidemia |
| 01/04/2001 | WO2000060102A3 Bacterial fimbrial system for presentation of heterologous peptide sequences |
| 01/04/2001 | WO2000058444A3 Adaptation of virus to vertebrate cells |
| 01/04/2001 | WO2000057917A3 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/04/2001 | WO2000057909A3 Attenuated dengue-2 virus vaccine |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000056358A3 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 01/04/2001 | WO2000055327A3 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 01/04/2001 | WO2000052045A3 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof |
| 01/04/2001 | WO2000039302A3 Improved expression of hiv polypeptides and production of virus-like particles |
| 01/04/2001 | WO2000038715A3 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | DE19930327A1 Inducing an immune response, e.g. to cancer cells or pathogens, comprises temporarily implanting an antigen in a housing that is impermeable to the antigen but permeable to the patient's antibodies |
| 01/04/2001 | CA2727172A1 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 01/04/2001 | CA2415095A1 Secreted alpha-helical protein-36 |
| 01/04/2001 | CA2380873A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | CA2377536A1 Novel compounds |
| 01/04/2001 | CA2377534A1 Delivery system |
| 01/04/2001 | CA2377531A1 Basb111 polypeptide and polynucleotide from moraxella catarrhalis |
| 01/04/2001 | CA2377462A1 Moraxella catarrhalis polypeptides |
| 01/04/2001 | CA2377433A1 Compound derived from an offset orf of the ice gene |
| 01/04/2001 | CA2377427A1 Glycosyltransferases of helicobacter pylori as a new target in prevention and teatment of h. pylori infections |
| 01/04/2001 | CA2377084A1 Methods and compositions for engineering of attenuated vaccines |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376926A1 Use of cpg as an adjuvant for malaria vaccine |
| 01/04/2001 | CA2376923A1 Prevention of type 1 diabetes and other non-polio enterovirus diseases |
| 01/04/2001 | CA2374610A1 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | CA2370887A1 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria |
| 01/04/2001 | CA2370687A1 Nucleic acid binding of multi-zinc finger transcription factors |
| 01/04/2001 | CA2370517A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | CA2370413A1 Hla binding peptides and their uses |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/03/2001 | EP1065212A2 Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines |
| 01/03/2001 | EP1064947A1 In ovo vaccination of 1 type marek's disease virus |
| 01/03/2001 | EP1064551A1 Development of human monoclonal antibodies and uses thereof |
| 01/03/2001 | EP1064550A1 AN EQUINE $i(NEOSPORA) ISOLATE AND ITS USES |
| 01/03/2001 | EP1064402A1 Antisense modulation of lfa-3 |
| 01/03/2001 | EP1064390A1 Enhanced anti-tumor immunity |
| 01/03/2001 | EP1064388A1 Human casb12 polypeptide, a serine protease |
| 01/03/2001 | EP1064380A1 EXPRESSION OF THE $i(INSL4) GENE IN HUMAN EMBRYONIC BONE TISSUES AND APPLICATIONS |
| 01/03/2001 | EP1064377A1 Casb414: antigen overexpressed in several tumours |
| 01/03/2001 | EP1064376A2 GFR$g(a)3 AND ITS USES |
| 01/03/2001 | EP1064372A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/03/2001 | EP1064371A2 Isolated mammalian membrane protein genes and related reagents |
| 01/03/2001 | EP1064366A1 $i(STAPHYLOCOCCUS AUREUS) GENES AND POLYPEPTIDES |
| 01/03/2001 | EP1064358A2 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
| 01/03/2001 | EP1064357A1 Processes for improved presentation of antigens by dendritic cells |
| 01/03/2001 | EP1064354A1 Compositions and methods for gene-based vaccines to provoke t cell responses |
| 01/03/2001 | EP1064308A1 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 01/03/2001 | EP1064307A1 Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof |
| 01/03/2001 | EP1064305A1 Recombinant virus |
| 01/03/2001 | EP1064303A1 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 01/03/2001 | EP1064027A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064025A2 Combined vaccine compositions |
| 01/03/2001 | EP1064024A1 Vaccines against circovirus infections |
| 01/03/2001 | EP1064023A1 Products in the treatment of cancer |
| 01/03/2001 | EP1064022A1 Hla-binding peptides and their uses |
| 01/03/2001 | EP1064014A2 Medicament for preventing or treating papilloma virus-specific tumors |
| 01/03/2001 | EP1064007A1 nrdG |
| 01/03/2001 | EP1064006A1 Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms |
| 01/03/2001 | EP1063997A2 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 01/03/2001 | EP1063985A1 Benzoates derivatives for inhibiting angiogenesis |
| 01/03/2001 | EP1063959A1 Sun-protection formulations active against herpes simplex viruses |
| 01/03/2001 | EP0816506B1 System for the expression of heterologous antigens as fusion proteins |
| 01/03/2001 | EP0807183B1 Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle |
| 01/03/2001 | CN1278865A Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| 01/03/2001 | CN1278864A Genetically modified tumor-targeted bacteria with reduced virulence |
| 01/03/2001 | CN1278739A Method of delivering genes to antigen presenting cells of the skin |
| 01/03/2001 | CN1278736A Hmanized antibodies to human gp39, compositions containing and therapeutic use thereof |
| 01/03/2001 | CN1278735A Vaginal suppository vaccine for urogenital infections |
| 01/03/2001 | CN1278734A Methods and compositions for treating rheumatoid arthritis |
| 01/03/2001 | CN1278557A Human protein kinase inhibitor gamma and its code sequence, preparation and use |
| 01/03/2001 | CN1278556A Human montage factor II and its code sequence, preparation and use |
| 01/03/2001 | CN1278555A New human stroma cell protein and its code sequence |
| 01/02/2001 | US6169175 Dna sequence encoding a variant m2 polypeptide of influenza a having a deletion of a domain, thus causing a reduction in hydrophobicity and an increase solubility in aqueous buffers |
| 01/02/2001 | US6169171 Dna sequence encoding a fusion protein including c-terminal portion of circumsporozoite protein, four or more tandem repeats of that protein immunodominant region, and surface antigen from hepatitis b virus; vaccines against malaria |
| 01/02/2001 | US6169069 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 01/02/2001 | US6168946 gp75 as a tumor vaccine for melanoma |
| 01/02/2001 | US6168943 Methods for making modified recombinant vesiculoviruses |
| 01/02/2001 | US6168942 Attenuated forms of bovine viral diarrhea virus |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168923 Compositions and methods for use of IL-12 as an adjuvant |
| 01/02/2001 | US6168804 Slow release antigen delivery systems; oligopeptide; monophosphoryl lipid a |
| 01/02/2001 | US6168796 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
| 01/02/2001 | US6168793 Heat shock protein 70 preparations in vaccination against cancer and infectious disease |
| 01/02/2001 | US6168791 Antibodies that bind immunomodulators |